SCORE | SCORE plus PDD | SCORE plus GCCVH | SCORE plus LLDASno | SCORE plus aPLpos | SCORE plus cUS | SCORE plus cfUS | ||||||||
Low risk | Moderate risk | Low risk | Moderate risk | Low risk | Moderate risk | Low risk | Moderate risk | Low risk | Moderate risk | Low risk | Moderate risk | Low risk | Moderate risk | |
Classification | ||||||||||||||
Risk enhancement* (%) | n/a | n/a | 34 | 66.7 | 27 | 57.6 | 35.9 | 33.3 | 17.7 | 21.2 | 8.5 | 39.4 | 9.9 | 54.6 |
9.4† | 11.5† | 9.4† | 38.5† | 10.9† | 53.9† | |||||||||
phi coefficient‡ | n/a | n/a | 0.06 | 0.13 | 0.23 | 0.20 | 0.07 | 0.16 | 0.03 | 0.18 | 0.92 | 0.74 | Ref. | Ref. |
0.06† | 0.33† | 0.92† | 0.73† | Ref. | Ref. | |||||||||
Eligibility | ||||||||||||||
% | 0 | 3 | 31.2 | 66.7 | 25.5 | 57.6 | 32 | 33.3 | 13.5 | 21.2 | 8.5 | 42.4 | 9.9 | 57.6 |
7.8† | 15.4† | 9.4† | 42.3† | 10.9† | 57.7† | |||||||||
Agreement‡ | ||||||||||||||
Cohen’s kappa | 0 | 0.05 | 0.07 | 0.10 | 0.21 | 0.26 | 0.08 | 0 | 0.01 | 0.16 | 0.92 | 0.70 | Ref. | Ref. |
0.08† | 0.24† | 0.91† | 0.70† | Ref. | Ref. |
PDD ≥10 years.
GCCVH ≥11 g.
*High-risk classification according to SCORE plus disease-related or vascular ultrasound risk classifiers.
†After exclusion of patients with aPLpos receiving antiplatelets.
‡Using SCORE plus cfUS as the reference modality for risk classification and eligibility.
aPLpos, antiphospholipid antibody positivity; cfUS, carotid-femoral ultrasound; cUS, carotid ultrasound; GCCVH, cumulative glucocorticoid ‘cardiovascular harm’ dose; LLDASno, failure to achieve lupus low disease activity state; n/a, not applicable; PDD, prolonged disease duration; ref, reference modality for risk classification and eligibility for lipid-lowering treatment; SCORE, Systematic Coronary Risk Evaluation; SLE, systemic lupus erythematosus.